{"filing":{"accession_number":"0001104659-26-073668","cik":"0001889109","ticker":"BLTE","company_name":"BELITE BIO, INC","form":"6-K","filing_date":"2026-06-15","report_date":null,"primary_document":"tm2617120d1_6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1889109/000110465926073668/tm2617120d1_6k.htm"},"events":[{"id":12211,"run_id":10774,"accession_number":"0001104659-26-073668","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"Belite Bio announced completion of a rolling New Drug Application (NDA) submission to the FDA for tinlarebant for Stargardt disease type 1, a rare inherited retinal disease with no approved treatments. The submission was made under Breakthrough Therapy Designation and represents a significant regulatory milestone for a clinical-stage company. While this is a material operational/regulatory event affecting the company's drug development pipeline and commercial prospects, it does not fit the specific event types (e.g., earnings_release, exec_departure, ma_activity) and is best classified as an operational milestone in the drug development process.","company_name":"BELITE BIO, INC","ticker":"BLTE","filing_date":"2026-06-15","form":"6-K","submitted_at":null,"items":[{"id":8998,"accession_number":"0001104659-26-073668","item_number":"EX-99.1","item_title":"tm2617120d1_ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Belite Bio announced completion of a rolling New Drug Application (NDA) submission to the FDA for tinlarebant for Stargardt disease type 1, a rare inherited retinal disease with no approved treatments. The submission was made under Breakthrough Therapy Designation and represents a significant regulatory milestone for a clinical-stage company. While this is a material operational/regulatory event affecting the company's drug development pipeline and commercial prospects, it does not fit the specific event types (e.g., earnings_release, exec_departure, ma_activity) and is best classified as an operational milestone in the drug development process.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-22T02:23:48.520921+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":8998,"accession_number":"0001104659-26-073668","item_number":"EX-99.1","item_title":"tm2617120d1_ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Belite Bio announced completion of a rolling New Drug Application (NDA) submission to the FDA for tinlarebant for Stargardt disease type 1, a rare inherited retinal disease with no approved treatments. The submission was made under Breakthrough Therapy Designation and represents a significant regulatory milestone for a clinical-stage company. While this is a material operational/regulatory event affecting the company's drug development pipeline and commercial prospects, it does not fit the specific event types (e.g., earnings_release, exec_departure, ma_activity) and is best classified as an operational milestone in the drug development process.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-22T02:23:48.520921+00:00","company_name":"BELITE BIO, INC","ticker":"BLTE","filing_date":"2026-06-15"}]}